Clinical Trials
60 trialsNCT06158841 2026-05-27
CERVINO
AbbVie
Phase 3 Recruiting
NCT07555938 2026-05-27
CEVOLUTION
Hoffmann-La Roche
Phase 3 Recruiting
NCT06152575 2026-05-22
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT05002816 2026-05-13
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Yale University
Phase 1/2 Active not recruiting
NCT05981209 2026-05-13
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT02420860 2026-04-15
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02719613 2026-04-15
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Completed
NCT04835129 2026-03-27
IMPEDE
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03361306 2026-03-06
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Completed
NCT05730036 2026-03-06
LINKER-MM3
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT02718833 2026-01-22
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02969837 2026-01-16
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT05560399 2026-01-02
CC-220
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Active not recruiting
NCT06518551 2025-12-11
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05028348 2025-12-04
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT06785415 2025-09-30
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Recruiting
NCT06163040 2025-07-31
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT03713294 2025-06-24
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01729091 2025-05-09
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04150965 2025-02-14
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Multiple Myeloma Research Consortium
Phase 1/2 Terminated
NCT03989414 2024-11-29
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
Phase 1/2 Active not recruiting
NCT02375555 2024-10-01
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03000634 2024-09-05
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
University of Arkansas
Phase 2 Withdrawn
NCT06232707 2024-05-31
ALUMMINATE
Celgene
Phase 3 Withdrawn
NCT02856438 2023-12-19
Early Patient Access Treatment Use Protocol CA204-220
Bristol-Myers Squibb
No longer available
NCT02843074 2023-12-05
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02368301 2023-11-30
Expanded Access Treatment Protocol CA204-143
Bristol-Myers Squibb
No longer available
NCT04614636 2023-09-21
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT03948035 2023-05-06
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Wuerzburg University Hospital
Phase 3 Active not recruiting
NCT03411031 2023-03-29
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02726581 2023-03-27
CheckMate 602
Bristol-Myers Squibb
Phase 3 Completed
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting
NCT02654132 2022-11-01
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Bristol-Myers Squibb
Phase 2 Completed
NCT01335399 2022-09-30
ELOQUENT - 1
Bristol-Myers Squibb
Phase 3 Completed
NCT02272803 2022-06-22
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
Bristol-Myers Squibb
Phase 2 Completed
NCT01239797 2022-06-01
ELOQUENT - 2
Bristol-Myers Squibb
Phase 3 Completed
NCT05170789 2022-05-04
ESdRRMM
Tulane University
Phase 2 Withdrawn
NCT03104270 2022-03-31
Combination Study for High Risk Multiple Myeloma Patients
Oncotherapeutics
Phase 2 Terminated
NCT03126617 2021-11-29
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Bristol-Myers Squibb
No longer available
NCT02495922 2021-09-10
GMMG-HD6
University of Heidelberg Medical Center
Phase 3 Completed
NCT04584307 2021-08-23
Immuno-POWER
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
NCT02612779 2021-07-02
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Bristol-Myers Squibb
Phase 2 Completed
NCT03003728 2020-07-10
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
University of Arkansas
Phase 2 Withdrawn
NCT03393273 2019-07-17
IFM2016-03
Assistance Publique - Hôpitaux de Paris
Phase 2 Withdrawn
NCT02159365 2019-07-16
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Bristol-Myers Squibb
Phase 2 Completed
NCT03168100 2019-01-28
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
University of Arkansas
Phase 2 Withdrawn
NCT03227432 2018-08-14
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Withdrawn